Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer

T. Einama, S. Homma, H. Kamachi, F. Kawamata, K. Takahashi, N. Takahashi, M. Taniguchi, T. Kamiyama, H. Furukawa, Y. Matsuno, S. Tanaka, Hiroshi Nishihara, A. Taketomi, S. Todo

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: Mesothelin is expressed in various types of malignant tumour, and we recently reported that expression of mesothelin was related to an unfavourable patient outcome in pancreatic ductal adenocarcinoma. In this study, we examined the clinicopathological significance of the mesothelin expression in gastric cancer, especially in terms of its association with the staining pattern. Methods: Tissue specimens from 110 gastric cancer patients were immunohistochemically examined. The staining proportion and intensity of mesothelin expression in tumour cells were analysed, and the localisation of mesothelin was classified into luminal membrane and/or cytoplasmic expression. Results: Mesothelin was positive in 49 cases, and the incidence of mesothelin expression was correlated with lymph-node metastasis. Furthermore, luminal membrane staining of mesothelin was identified in 16 cases, and the incidence of luminal membrane expression was also correlated with pT factor, pStage, lymphatic permeation, blood vessel permeation, recurrence, and poor patient outcome. Multivariate analysis showed that luminal membrane expression of mesothelin was an independent predictor of overall patient survival. Conclusion: We described that the luminal membrane expression of mesothelin was a reliable prognostic factor in gastric cancer, suggesting the functional significance of membrane-localised mesothelin in the aggressive behaviour of gastric cancer cells.

Original languageEnglish
Pages (from-to)137-142
Number of pages6
JournalBritish Journal of Cancer
Volume107
Issue number1
DOIs
Publication statusPublished - 2012 Jun 26
Externally publishedYes

Fingerprint

Stomach Neoplasms
Membranes
Staining and Labeling
mesothelin
Incidence
Blood Vessels
Neoplasms
Adenocarcinoma
Multivariate Analysis
Lymph Nodes
Cell Membrane
Neoplasm Metastasis
Recurrence
Survival

Keywords

  • gastric cancer
  • luminal membrane expression
  • Mesothelin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Einama, T., Homma, S., Kamachi, H., Kawamata, F., Takahashi, K., Takahashi, N., ... Todo, S. (2012). Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer. British Journal of Cancer, 107(1), 137-142. https://doi.org/10.1038/bjc.2012.235

Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer. / Einama, T.; Homma, S.; Kamachi, H.; Kawamata, F.; Takahashi, K.; Takahashi, N.; Taniguchi, M.; Kamiyama, T.; Furukawa, H.; Matsuno, Y.; Tanaka, S.; Nishihara, Hiroshi; Taketomi, A.; Todo, S.

In: British Journal of Cancer, Vol. 107, No. 1, 26.06.2012, p. 137-142.

Research output: Contribution to journalArticle

Einama, T, Homma, S, Kamachi, H, Kawamata, F, Takahashi, K, Takahashi, N, Taniguchi, M, Kamiyama, T, Furukawa, H, Matsuno, Y, Tanaka, S, Nishihara, H, Taketomi, A & Todo, S 2012, 'Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer', British Journal of Cancer, vol. 107, no. 1, pp. 137-142. https://doi.org/10.1038/bjc.2012.235
Einama T, Homma S, Kamachi H, Kawamata F, Takahashi K, Takahashi N et al. Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer. British Journal of Cancer. 2012 Jun 26;107(1):137-142. https://doi.org/10.1038/bjc.2012.235
Einama, T. ; Homma, S. ; Kamachi, H. ; Kawamata, F. ; Takahashi, K. ; Takahashi, N. ; Taniguchi, M. ; Kamiyama, T. ; Furukawa, H. ; Matsuno, Y. ; Tanaka, S. ; Nishihara, Hiroshi ; Taketomi, A. ; Todo, S. / Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer. In: British Journal of Cancer. 2012 ; Vol. 107, No. 1. pp. 137-142.
@article{dce0c645588246c1b526b8db0d1102a7,
title = "Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer",
abstract = "Background: Mesothelin is expressed in various types of malignant tumour, and we recently reported that expression of mesothelin was related to an unfavourable patient outcome in pancreatic ductal adenocarcinoma. In this study, we examined the clinicopathological significance of the mesothelin expression in gastric cancer, especially in terms of its association with the staining pattern. Methods: Tissue specimens from 110 gastric cancer patients were immunohistochemically examined. The staining proportion and intensity of mesothelin expression in tumour cells were analysed, and the localisation of mesothelin was classified into luminal membrane and/or cytoplasmic expression. Results: Mesothelin was positive in 49 cases, and the incidence of mesothelin expression was correlated with lymph-node metastasis. Furthermore, luminal membrane staining of mesothelin was identified in 16 cases, and the incidence of luminal membrane expression was also correlated with pT factor, pStage, lymphatic permeation, blood vessel permeation, recurrence, and poor patient outcome. Multivariate analysis showed that luminal membrane expression of mesothelin was an independent predictor of overall patient survival. Conclusion: We described that the luminal membrane expression of mesothelin was a reliable prognostic factor in gastric cancer, suggesting the functional significance of membrane-localised mesothelin in the aggressive behaviour of gastric cancer cells.",
keywords = "gastric cancer, luminal membrane expression, Mesothelin",
author = "T. Einama and S. Homma and H. Kamachi and F. Kawamata and K. Takahashi and N. Takahashi and M. Taniguchi and T. Kamiyama and H. Furukawa and Y. Matsuno and S. Tanaka and Hiroshi Nishihara and A. Taketomi and S. Todo",
year = "2012",
month = "6",
day = "26",
doi = "10.1038/bjc.2012.235",
language = "English",
volume = "107",
pages = "137--142",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer

AU - Einama, T.

AU - Homma, S.

AU - Kamachi, H.

AU - Kawamata, F.

AU - Takahashi, K.

AU - Takahashi, N.

AU - Taniguchi, M.

AU - Kamiyama, T.

AU - Furukawa, H.

AU - Matsuno, Y.

AU - Tanaka, S.

AU - Nishihara, Hiroshi

AU - Taketomi, A.

AU - Todo, S.

PY - 2012/6/26

Y1 - 2012/6/26

N2 - Background: Mesothelin is expressed in various types of malignant tumour, and we recently reported that expression of mesothelin was related to an unfavourable patient outcome in pancreatic ductal adenocarcinoma. In this study, we examined the clinicopathological significance of the mesothelin expression in gastric cancer, especially in terms of its association with the staining pattern. Methods: Tissue specimens from 110 gastric cancer patients were immunohistochemically examined. The staining proportion and intensity of mesothelin expression in tumour cells were analysed, and the localisation of mesothelin was classified into luminal membrane and/or cytoplasmic expression. Results: Mesothelin was positive in 49 cases, and the incidence of mesothelin expression was correlated with lymph-node metastasis. Furthermore, luminal membrane staining of mesothelin was identified in 16 cases, and the incidence of luminal membrane expression was also correlated with pT factor, pStage, lymphatic permeation, blood vessel permeation, recurrence, and poor patient outcome. Multivariate analysis showed that luminal membrane expression of mesothelin was an independent predictor of overall patient survival. Conclusion: We described that the luminal membrane expression of mesothelin was a reliable prognostic factor in gastric cancer, suggesting the functional significance of membrane-localised mesothelin in the aggressive behaviour of gastric cancer cells.

AB - Background: Mesothelin is expressed in various types of malignant tumour, and we recently reported that expression of mesothelin was related to an unfavourable patient outcome in pancreatic ductal adenocarcinoma. In this study, we examined the clinicopathological significance of the mesothelin expression in gastric cancer, especially in terms of its association with the staining pattern. Methods: Tissue specimens from 110 gastric cancer patients were immunohistochemically examined. The staining proportion and intensity of mesothelin expression in tumour cells were analysed, and the localisation of mesothelin was classified into luminal membrane and/or cytoplasmic expression. Results: Mesothelin was positive in 49 cases, and the incidence of mesothelin expression was correlated with lymph-node metastasis. Furthermore, luminal membrane staining of mesothelin was identified in 16 cases, and the incidence of luminal membrane expression was also correlated with pT factor, pStage, lymphatic permeation, blood vessel permeation, recurrence, and poor patient outcome. Multivariate analysis showed that luminal membrane expression of mesothelin was an independent predictor of overall patient survival. Conclusion: We described that the luminal membrane expression of mesothelin was a reliable prognostic factor in gastric cancer, suggesting the functional significance of membrane-localised mesothelin in the aggressive behaviour of gastric cancer cells.

KW - gastric cancer

KW - luminal membrane expression

KW - Mesothelin

UR - http://www.scopus.com/inward/record.url?scp=84863006209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863006209&partnerID=8YFLogxK

U2 - 10.1038/bjc.2012.235

DO - 10.1038/bjc.2012.235

M3 - Article

VL - 107

SP - 137

EP - 142

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 1

ER -